Is the business good?
How good a business is ANAB?
AnaptysBio, Inc. keeps 18% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
18%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- −6.4%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | −32% |
| FY2021 | −90% |
| FY2022 | −1119% |
| FY2023 | −958% |
| FY2024 | −126% |
| FY2025 | 20% |
Details›
- Operating margin12 months to Q1 2026
- 18%
- Net margin12 months to Q1 2026
- −12%
- Free cash flow margin
- 1.9%
- Revenue, trailing twelve months
- $232M
- Free cash flow, trailing twelve months
- $4.4M
- Net income, trailing twelve months
- −$27M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Biotechnology
Ranks #102 of 145 by Smart Score